Effect/JJ
of/IN
Genetic/JJ
Predisposition/NN
on/IN
Blood/NN
Lipid/NN
Traits/NNS
Using/VBG
Cumulative/JJ
Risk/NN
Assessment/JJ
in/IN
the/DT
Korean/JJ
Population/NN
./.
====================
Dyslipidemia/NN
,/,
mainly/RB
characterized/VBN
by/IN
high/JJ
triglyceride/NN
(/(
TG/NN
)/)
and/CC
low/JJ
high-density/JJ
lipoprotein/NN
cholesterol/NN
(/(
HDL-C/NN
)/)
levels/NNS
,/,
is/VBZ
an/DT
important/JJ
etiological/JJ
factor/NN
in/IN
the/DT
development/NN
of/IN
cardiovascular/JJ
disease/NN
(/(
CVD/NN
)/)
./.
====================
Considering/VBG
the/DT
relationship/NN
between/IN
childhood/NN
obesity/NN
and/CC
CVD/NN
risk/NN
,/,
it/PRP
would/MD
be/VB
worthwhile/JJ
to/TO
evaluate/VB
whether/IN
previously/RB
identified/VBN
lipid-related/JJ
variants/NNS
in/IN
adult/JJ
subjects/NNS
are/VBP
associated/VBN
with/IN
lipid/NN
variations/NNS
in/IN
a/DT
childhood/NN
obesity/NN
study/NN
(/(
n/NN
=/JJ
482/CD
)/)
./.
====================
In/IN
an/DT
association/NN
analysis/NN
for/IN
16/CD
genome-wide/NN
association/NN
study/NN
(/(
GWAS/NN
)/)
-based/JJ
candidate/NN
loci/NNS
,/,
we/PRP
confirmed/VBD
significant/JJ
associations/NNS
of/IN
a/DT
genetic/JJ
predisposition/NN
to/TO
lipoprotein/NN
concentrations/NNS
in/IN
a/DT
childhood/NN
obesity/NN
study/NN
./.
====================
Having/VBG
two/CD
loci/NNS
(/(
rs10503669/CD
at/IN
LPL/NN
and/CC
rs16940212/NN
at/IN
LIPC/NN
)/)
that/WDT
showed/VBD
the/DT
strongest/JJS
association/NN
with/IN
blood/NN
levels/NNS
of/IN
TG/NN
and/CC
HDL-C/NN
,/,
we/PRP
calculated/VBD
a/DT
genetic/JJ
risk/NN
score/RB
(/(
GRS/NN
)/)
,/,
representing/VBG
the/DT
sum/NN
of/IN
the/DT
risk/NN
alleles/NNS
./.
====================
It/PRP
has/VBZ
been/VBN
observed/VBN
that/IN
increasing/VBG
GRS/NN
is/VBZ
significantly/RB
associated/VBN
with/IN
decreased/VBN
HDL-C/NN
(/(
effect/NN
size/NN
,/,
-1.13/CD
±/CD
0.07/CD
)/)
compared/VBD
to/TO
single/JJ
nucleotide/NN
polymorphism/NN
combinations/NNS
without/IN
two/CD
risk/NN
variants/NNS
./.
====================
In/IN
addition/NN
,/,
a/DT
positive/JJ
correlation/NN
was/VBD
observed/VBN
between/IN
allelic/JJ
dosage/NN
score/RB
and/CC
risk/NN
allele/NN
(/(
rs10503669/CD
at/IN
LPL/NN
)/)
on/IN
high/JJ
TG/NN
levels/NNS
(/(
effect/NN
size/NN
,/,
10.89/CD
±/CD
0.84/CD
)/)
./.
====================
These/DT
two/CD
loci/NNS
yielded/VBD
consistent/JJ
associations/NNS
in/IN
our/PRP$
previous/JJ
meta-analysis/NN
./.
====================
Taken/VBN
together/RB
,/,
our/PRP$
findings/NNS
demonstrate/VBP
that/IN
the/DT
genetic/JJ
architecture/NN
of/IN
circulating/VBG
lipid/NN
levels/NNS
(/(
TG/NN
and/CC
HDL-C/NN
)/)
overlap/VBP
to/TO
a/DT
large/JJ
extent/NN
in/IN
childhood/NN
as/IN
well/RB
as/IN
in/IN
adulthood/NN
./.
====================
Post-GWAS/JJ
functional/JJ
characterization/NN
of/IN
these/DT
variants/NNS
is/VBZ
further/RBR
required/VBN
to/TO
elucidate/VB
their/PRP$
pathophysiological/JJ
roles/NNS
and/CC
biological/JJ
mechanisms/NNS
./.
====================
Dyslipidemia/NN
is/VBZ
an/DT
important/JJ
etiological/JJ
factor/NN
in/IN
the/DT
development/NN
of/IN
cardiovascular/JJ
disease/NN
(/(
CVD/NN
)/)
,/,
which/WDT
is/VBZ
the/DT
leading/VBG
cause/VBP
of/IN
deaths/NNS
for/IN
adults/NNS
./.
====================
Dyslipidemia/NN
is/VBZ
mainly/RB
characterized/VBN
by/IN
elevated/JJ
levels/NNS
of/IN
triglycerides/NNS
(/(
TGs/NNS
)/)
,/,
increased/VBD
low-density/JJ
lipoprotein/NN
cholesterol/NN
(/(
LDL-C/NN
)/)
,/,
and/CC
reduced/VBD
high-density/JJ
lipoprotein/NN
cholesterol/NN
(/(
HDL-C/NN
)/)
[/(
1/CD
]/)
./.
====================
In/IN
the/DT
past/NN
few/JJ
years/NNS
,/,
genome-wide/NN
association/NN
studies/NNS
(/(
GWASs/NNS
)/)
and/CC
meta-analyses/NNS
have/VBP
identified/VBN
common/JJ
genetic/JJ
variants/NNS
that/DT
contribute/VBP
to/TO
blood/NN
lipid/NN
phenotypes/NNS
in/IN
Caucasian-based/JJ
populations/NNS
[/(
2-8/CD
]/)
./.
====================
In/IN
addition/NN
,/,
we/PRP
have/VBP
convincingly/RB
mapped/VBD
16/CD
loci/NNS
for/IN
major/JJ
lipoprotein/NN
concentrations/NNS
(/(
TG/NN
,/,
HDL-C/NN
,/,
and/CC
LDL-C/NN
)/)
in/IN
a/DT
two-stage/JJ
association/NN
study/NN
in/IN
individuals/NNS
of/IN
East/JJ
Asian/JJ
ancestry/NN
[/(
9/CD
]/)
./.
====================
Given/IN
the/DT
growing/VBG
global/JJ
epidemic/JJ
of/IN
metabolic/JJ
syndrome/NN
,/,
including/VBG
obesity/NN
and/CC
type/NN
2/CD
diabetes/NNS
(/(
T2D/NN
)/)
,/,
lipoprotein/NN
metabolism/NN
disorders/NNS
have/VBP
become/VBN
an/DT
important/JJ
health/NN
problem/NN
in/IN
adulthood/JJ
but/CC
also/RB
have/VBP
emerged/VBN
as/IN
an/DT
increasingly/RB
prevalent/JJ
risk/NN
factor/NN
in/IN
childhood/NN
[/(
10/CD
]/)
./.
====================
Although/IN
many/JJ
GWASs/NNS
and/CC
meta-analyses/NNS
have/VBP
provided/VBN
susceptibility/NN
genes/NNS
or/CC
loci/NNS
for/IN
lipid-related/JJ
traits/VBZ
from/IN
multiple/JJ
large/JJ
population-based/JJ
cohorts/NNS
of/IN
adults/NNS
,/,
it/PRP
is/VBZ
of/IN
great/JJ
importance/NN
to/TO
evaluate/VB
genetic/JJ
predisposition/NN
at/IN
an/DT
early/JJ
age/NN
./.
====================
However/RB
,/,
little/JJ
is/VBZ
known/VBN
about/IN
their/PRP$
genetic/JJ
effects/NNS
in/IN
a/DT
younger/JJR
population/NN
./.
====================
Moreover/RB
,/,
most/JJS
identified/VBN
variants/NNS
have/VBP
shown/VBN
modest/IN
effects/NNS
and/CC
have/VBP
explained/VBN
only/RB
a/DT
small/JJ
proportion/NN
of/IN
heritable/JJ
components/NNS
for/IN
disease/NN
risk/NN
[/(
11/CD
]/)
./.
====================
Nevertheless/RB
,/,
when/WRB
multiple/JJ
genetic/JJ
markers/NNS
are/VBP
considered/VBN
together/RB
,/,
literature-based/VBN
genetic/JJ
risk/NN
scores/NNS
might/MD
be/VB
useful/JJ
in/IN
improving/VBG
the/DT
identification/NN
of/IN
the/DT
genetic/JJ
contribution/NN
in/IN
those/DT
at/IN
high/JJ
risk/NN
of/IN
disease/NN
[/(
12-14/CD
]/)
./.
====================
Therefore/RB
,/,
the/DT
aim/NN
of/IN
this/DT
study/NN
was/VBD
to/TO
consolidate/VB
the/DT
associations/NNS
of/IN
GWAS-based/JJ
candidate/NN
variants/NNS
with/IN
blood/NN
lipid/NN
concentrations/NNS
in/IN
a/DT
childhood/NN
obesity/NN
study/NN
and/CC
to/TO
evaluate/VB
genetic/JJ
risk/NN
scores/NNS
(/(
GRS/NN
)/)
for/IN
lipid-related/JJ
risk/NN
phenotypes/NNS
./.
====================
Study/NN
subjects/NNS
====================
Korean/JJ
Association/NN
Resource/NN
(/(
KARE/NN
)/)
study/NN
was/VBD
collected/VBN
through/IN
the/DT
Korean/JJ
Genome/NN
Epidemiologic/JJ
Study/NN
project/VB
-/:
in/IN
total/JJ
,/,
10,038/CD
people/JJ
,/,
40-69/CD
years/NNS
old/JJ
,/,
living/VBG
in/IN
Ansung/JJ
and/CC
Ansan/NN
,/,
from/IN
2001-2002/CD
./.
====================
For/IN
more/RBR
information/NN
,/,
the/DT
study/NN
has/VBZ
already/RB
been/VBN
reported/VBN
[/(
9/CD
,/,
15/CD
]/)
./.
====================
The/DT
Health/NN
Examinee/NN
cohort/NN
(/(
HEXA/NN
)/)
shared/VBN
project/JJ
is/VBZ
a/DT
community-based/JJ
epidemiological/JJ
cohort/NN
of/IN
1,200,000/CD
subjects/NNS
(/(
aged/JJ
,/,
40-69/CD
)/)
who/WP
were/VBD
recruited/VBN
for/IN
baseline/NN
examination/NN
from/IN
2004/CD
to/TO
2009/CD
./.
====================
To/TO
share/VB
the/DT
controls/NNS
,/,
4,302/CD
subjects/NNS
were/VBD
randomly/RB
selected/VBN
to/TO
participate/VB
between/IN
2006/CD
and/CC
2007/CD
./.
====================
The/DT
BioBank/NN
Japan/NNP
study/NN
was/VBD
approved/VBN
by/IN
the/DT
ethical/JJ
committees/NNS
in/IN
the/DT
Institute/JJ
of/IN
Medical/JJ
Science/NNP
,/,
the/DT
University/NN
of/IN
Tokyo/JJ
,/,
and/CC
the/DT
Center/JJ
for/IN
Genomic/JJ
Medicine/NN
,/,
RIKEN/NN
./.
====================
Subjects/NNS
for/IN
the/DT
Health2/NN
cohorts/NNS
for/IN
the/DT
replication/NN
study/NN
were/VBD
selected/VBN
from/IN
another/DT
community-based/VBN
cohort/NN
sample/NN
provided/VBD
by/IN
the/DT
Health2/NN
study/NN
,/,
as/IN
described/VBN
previously/RB
[/(
15/CD
]/)
./.
====================
We/PRP
examined/VBD
7,861/CD
selected/VBN
from/IN
the/DT
8,500/CD
participants/NNS
(/(
aged/JJ
,/,
40-69/CD
)/)
./.
====================
The/DT
students/NNS
aged/JJ
9/CD
and/CC
12/CD
years/NNS
were/VBD
recruited/VBN
from/IN
Gwacheon/JJ
City/NN
and/CC
Gyeonggi/NNP
Province/NN
between/IN
April/NN
and/CC
June/NN
2010/CD
./.
====================
This/DT
study/NN
was/VBD
conducted/VBN
as/IN
part/NN
of/IN
the/DT
Korean/JJ
Children-Adolescents/NNS
Study/NN
(/(
KoCAS/NN
)/)
,/,
which/WDT
has/VBZ
been/VBN
monitored/VBN
yearly/RB
since/IN
their/PRP$
entry/NN
into/IN
elementary/JJ
school/NN
at/IN
age/NN
7/CD
in/IN
Gwacheon/JJ
City/NN
or/CC
fourth/IN
grade/NN
at/IN
age/NN
10/CD
in/IN
Seoul/JJ
and/CC
Gyeonggi/NNP
Province/NN
,/,
Korea/NN
./.
====================
Subjects/NNS
who/WP
were/VBD
enrolled/VBN
in/IN
a/DT
specific/JJ
diet/NN
program/NN
or/CC
were/VBD
taking/VBG
any/DT
medications/NNS
known/VBN
to/TO
affect/VB
appetite/JJ
were/VBD
excluded/VBN
from/IN
the/DT
study/NN
./.
====================
The/DT
study/NN
protocol/NN
was/VBD
approved/VBN
by/IN
the/DT
institutional/JJ
review/NN
board/JJ
of/IN
Seoul-Paik/NN
Hospital/JJ
,/,
Inje/NNP
University/NN
,/,
and/CC
the/DT
Korea/NN
Center/NN
for/IN
Disease/NN
Control/NN
and/CC
Prevention/NN
./.
====================
Informed/VBN
consent/NN
was/VBD
obtained/VBN
from/IN
the/DT
children/NN
's/POS
parents/NNS
./.
====================
Genotyping/VBG
====================
KARE/NN
samples/NNS
were/VBD
genotyped/VBN
using/VBG
Affymetrix/JJ
Genome-Wide/NN
Human/JJ
SNP/NN
array/NN
5.0/CD
(/(
Affymetrix/JJ
,/,
Santa/NN
Clara/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
and/CC
processed/VBN
by/IN
Bayesian/JJ
Robust/NNP
Linear/JJ
Modeling/JJ
using/VBG
the/DT
Mahalanobis/NN
Distance/NN
(/(
BRLMM/NN
)/)
genotyping/VBG
algorithm/NN
[/(
16/CD
]/)
./.
====================
The/DT
HEXA/NN
shared/VBN
sample/NN
was/VBD
genotyped/VBN
using/VBG
Affymetrix/JJ
Genome-Wide/NN
Human/JJ
SNP/NN
array/NN
6.0/CD
and/CC
processed/VBN
with/IN
the/DT
Birdseed/JJ
Genotyping/JJ
Algorithm/NN
[/(
17/CD
]/)
./.
====================
The/DT
BioBank/NN
Japan/NNP
study/NN
was/VBD
genotyped/VBN
using/VBG
the/DT
Illumina/NN
Human610-Quad/JJ
BeadChip/NN
(/(
Illumina/NN
Inc./NNP
,/,
San/JJ
Diego/NN
,/,
CA/NN
,/,
USA/NN
)/)
./.
====================
A/DT
childhood/NN
obesity/NN
study/NN
was/VBD
genotyped/VBN
using/VBG
the/DT
Illumina/NN
Omni1-Quad/JJ
BeadChip/NN
./.
====================
Individuals/NNS
were/VBD
excluded/VBN
as/IN
follows/VBZ
:/:
genotyping/VBG
call/JJ
rate/NN
,/,
sex/NN
inconsistency/NN
,/,
heterozygosity/NN
,/,
identity-by-state/VBP
value/NN
,/,
and/CC
any/DT
kinds/NNS
of/IN
tumor/NN
./.
====================
For/IN
more/RBR
information/NN
,/,
the/DT
study/NN
has/VBZ
been/VBN
reported/VBN
[/(
15/CD
]/)
./.
====================
For/IN
the/DT
replication/NN
study/RB
in/IN
Health2/NN
(/(
7,861/CD
)/)
,/,
we/PRP
performed/VBD
a/DT
genotype/JJ
assay/NN
using/VBG
the/DT
TaqMan/JJ
reaction/NN
for/IN
four/CD
single/JJ
nucleotide/NN
polymorphisms/NNS
(/(
SNPs/NNS
)/)
(/(
rs2074356/NN
,/,
rs16940212/NN
,/,
rs12708980/RB
,/,
rs599839/NN
)/)
and/CC
the/DT
GoldenGate/JJ
assay/NN
(/(
Illumina/NN
Inc./NNP
)/)
for/IN
nine/CD
SNPs/NNS
(/(
rs780092/NN
,/,
rs10503669/RB
,/,
rs2001945/NN
,/,
rs603446/RB
,/,
rs12686004/NN
,/,
rs11216126/RB
,/,
rs12229654/NN
,/,
rs519113/RB
,/,
rs12654264/NN
,/,
rs2738446/RB
)/)
./.
====================
To/TO
analyze/VB
the/DT
quality/NN
control/NN
,/,
we/PRP
conducted/VBD
duplicate/VBP
genotyping/VBG
using/VBG
1-2.5/CD
%/NN
of/IN
samples/NNS
./.
====================
For/IN
further/RBR
association/NN
analyses/NNS
,/,
concordance/NN
rates/NNS
were/VBD
satisfied/VBN
with/IN
duplicates/NNS
of/IN
over/IN
99/CD
%/NN
and/CC
a/DT
genotype/JJ
success/NN
rate/NN
of/IN
over/IN
98/CD
%/NN
./.
====================
SNP/NN
imputation/NN
====================
In/IN
each/DT
GWAS/NN
data/NNS
point/VBP
,/,
imputation/NN
analysis/NN
was/VBD
performed/VBN
using/VBG
the/DT
IMPUTE/NN
reference/VBP
HapMap/NN
Asian/JJ
(/(
Japanese/JJ
[/(
JPT/NN
]/)
/Han/JJ
Chinese/JJ
[/(
CHB/NN
]/)
)/)
population/NN
panel/NN
,/,
based/VBN
on/IN
NCBI/NN
build/JJ
36/CD
and/CC
dbSNP/NN
build/JJ
129/CD
./.
====================
Of/IN
these/DT
,/,
in/IN
each/DT
cohort/NN
,/,
we/PRP
dropped/VBD
SNPs/NNS
with/IN
a/DT
posterior/JJ
probability/NN
score/RB
</JJR
0.90/CD
,/,
high/JJ
genotype/NN
information/NN
content/NN
(/(
info/RB
</JJR
0.5/CD
)/)
,/,
Hardy-Weinberg/JJ
equilibrium/NN
(/(
HWE/NNP
)/)
(/(
p/NN
</JJR
1/CD
×/NN
10-7/CD
)/)
,/,
SNP/NN
missing/VBG
rate/NN
>/JJR
0.1/CD
,/,
and/CC
minor/JJ
allele/NN
frequency/NN
(/(
MAF/NN
)/)
</JJR
0.01/CD
./.
====================
In/IN
the/DT
former/JJ
analysis/NN
,/,
only/RB
imputed/JJ
SNPs/NNS
that/DT
satisfied/JJ
the/DT
genomewide/NN
SNP/NN
quality/NN
control/NN
criteria/NNS
were/VBD
considered/VBN
./.
====================
Association/NN
analysis/NN
====================
In/IN
performing/VBG
the/DT
association/NN
tests/NNS
,/,
SNPs/NNS
were/VBD
analyzed/VBN
with/IN
PLINK/NN
(/(
http/NN
:/:
//pngu.mgh.harvard.edu/~purcell/plink//JJ
)/)
and/CC
SAS/NN
version/NN
9.1/CD
(/(
SAS/NN
institute/JJ
Inc./NNP
,/,
Cary/NN
,/,
NC/NN
,/,
USA/NNP
)/)
./.
====================
Individuals/NNS
who/WP
were/VBD
on/IN
lipid-lowering/JJ
therapy/NN
and/CC
hypertensive/JJ
medications/NNS
were/VBD
excluded/VBN
for/IN
dyslipidemia-related/VBN
phenotypes/NNS
,/,
such/JJ
as/IN
TG/NN
,/,
HDL-C/NN
,/,
and/CC
LDL-C./NN
LDL-C/NN
concentrations/NNS
were/VBD
calculated/VBN
with/IN
Friedewald/JJ
's/POS
formula/FW
[/(
18/CD
]/)
./.
====================
Missing/VBG
values/NNS
were/VBD
assigned/VBN
for/IN
individuals/NNS
with/IN
TG/NN
over/IN
400/CD
mg/dL/NN
./.
====================
The/DT
dyslipidemia-related/VBN
phenotypes/NNS
were/VBD
tested/VBN
by/IN
multivariate/JJ
linear/JJ
regression/NN
analysis/NN
in/IN
an/DT
additive/JJ
genetic/JJ
model/NN
(/(
1-d.f/JJ
./.
====================
)/)
,/,
including/VBG
age/NN
,/,
sex/NN
,/,
and/CC
recruitment/NN
area/NN
as/IN
covariates/VBZ
./.
====================
TG/NN
and/CC
HDL-C/NN
were/VBD
transformed/VBN
prior/JJ
to/TO
analysis/NN
using/VBG
natural/JJ
log/NN
transformation/NN
to/TO
remove/VB
skewing/NN
./.
====================
LDL-C/NN
was/VBD
normally/RB
distributed/VBN
,/,
and/CC
no/DT
transformations/NNS
were/VBD
required/VBN
./.
====================
A/DT
GRS/NN
was/VBD
examined/VBN
using/VBG
multivariate/JJ
linear/JJ
regression/NN
analysis/NN
,/,
adjusting/VBG
for/IN
age/NN
,/,
sex/NN
,/,
and/CC
recruitment/NN
area/NN
./.
====================
The/DT
clinical/JJ
characteristics/NNS
and/CC
statistics/NNS
of/IN
the/DT
variables/NNS
for/IN
each/DT
study/NN
sample/NN
are/VBP
described/VBN
in/IN
Table/JJ
1/CD
./.
====================
Our/PRP$
previous/JJ
large-scale/JJ
GWAS/NN
identified/VBN
9/CD
novel/JJ
and/CC
24/CD
known/VBN
genetic/JJ
loci/NNS
influencing/VBG
metabolic/JJ
traits/VBZ
in/IN
East/JJ
Asians/NNS
[/(
9/CD
]/)
./.
====================
In/IN
an/DT
attempt/NN
to/TO
determine/VB
whether/IN
well-established/JJ
lipid-related/JJ
variants/NNS
contribute/VBP
to/TO
significant/JJ
and/CC
reproducible/JJ
genetic/JJ
factors/NNS
for/IN
susceptibility/NN
to/TO
blood/NN
lipid/NN
concentrations/NNS
in/IN
a/DT
childhood/NN
obesity/NN
study/NN
,/,
we/PRP
first/RB
examined/VBN
the/DT
associations/NNS
between/IN
individual/JJ
genetic/JJ
variants/NNS
and/CC
lipid-related/JJ
phenotypes/NNS
using/VBG
linear/JJ
regression/NN
analysis/NN
./.
====================
Of/IN
these/DT
16/CD
SNPs/NNS
for/IN
blood/NN
lipid/NN
traits/VBZ
,/,
rs10503669/NN
in/IN
LPL/NN
(/(
genotyped/VBN
SNP/NN
in/IN
a/DT
childhood/NN
obesity/NN
study/NN
)/)
was/VBD
significantly/RB
associated/VBN
with/IN
TG/NN
and/CC
HDL-C/NN
,/,
respectively/RB
./.
====================
In/IN
addition/NN
,/,
rs16940212/NN
in/IN
LIPC/NN
(/(
linkage/NN
disequilibrium-based/VBN
proxy/NN
SNP/NN
)/)
was/VBD
associated/VBN
with/IN
HDL-C/NN
(/(
Table/JJ
2/CD
)/)
./.
====================
The/DT
direction/JJ
of/IN
these/DT
associations/NNS
was/VBD
consistent/JJ
with/IN
our/PRP$
previous/JJ
GWAS/NN
[/(
9/CD
]/)
./.
====================
Having/VBG
two/CD
loci/NNS
(/(
rs10503669/CD
at/IN
LPL/NN
and/CC
rs16940212/NN
at/IN
LIPC/NN
)/)
showing/VBG
the/DT
strongest/JJS
association/NN
with/IN
TG/NN
and/CC
HDL-C/NN
,/,
we/PRP
next/RB
investigated/VBD
whether/IN
the/DT
cumulative/JJ
allelic/JJ
dosage/NN
of/IN
risk/NN
alleles/NNS
contributes/VBZ
to/TO
the/DT
quantitative/JJ
variation/NN
of/IN
lipoprotein/NN
concentrations/NNS
in/IN
the/DT
KARE/NN
study/NN
using/VBG
a/DT
method/NN
of/IN
calculating/JJ
a/DT
GRS/NN
./.
====================
We/PRP
evaluated/VBD
the/DT
joint/NN
effects/NNS
of/IN
the/DT
best-associated/VBN
SNPs/NNS
at/IN
the/DT
two/CD
loci/NNS
showing/VBG
evidence/NN
of/IN
association/NN
with/IN
HDL-C/NN
(/(
rs10503669/NN
at/IN
LPL/NN
and/CC
rs16940212/NN
at/IN
LIPC/NN
)/)
./.
====================
We/PRP
calculated/VBD
a/DT
GRS/NN
,/,
representing/VBG
the/DT
sum/NN
of/IN
the/DT
risk/NN
alleles/NNS
,/,
and/CC
observed/VBN
that/IN
increasing/VBG
GRS/NN
was/VBD
significantly/RB
associated/VBN
with/IN
decreased/VBN
HDL-C/NN
(/(
effect/NN
size/NN
,/,
-1.13/CD
±/CD
0.07/CD
)/)
compared/VBN
to/TO
SNP/NN
combinations/NNS
without/IN
two/CD
risk/NN
variants/NNS
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
In/IN
addition/NN
,/,
a/DT
positive/JJ
correlation/NN
was/VBD
observed/VBN
between/IN
allelic/JJ
dosage/NN
score/RB
and/CC
risk/NN
allele/NN
(/(
rs10503669/CD
at/IN
LPL/NN
)/)
for/IN
high/JJ
TG/NN
levels/NNS
(/(
effect/NN
size/NN
,/,
10.89/CD
±/CD
0.84/CD
)/)
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
Blood/NN
lipid/NN
levels/NNS
are/VBP
an/DT
important/JJ
etiological/JJ
contributor/NN
to/TO
CVD/NN
./.
====================
CVD/NN
is/VBZ
the/DT
leading/VBG
cause/VBP
of/IN
death/NN
among/IN
individuals/NNS
with/IN
T2D/NN
,/,
in/IN
which/WDT
lipid/NN
abnormalities/NNS
are/VBP
characterized/VBN
by/IN
hypertriglyceridemia/NN
,/,
reduced/VBD
levels/NNS
of/IN
HDL-C/NN
,/,
and/CC
elevated/JJ
levels/NNS
of/IN
LDL-C/NN
./.
====================
These/DT
lipid-related/JJ
traits/VBZ
,/,
including/VBG
~14-54/CD
%/NN
for/IN
TG/NN
,/,
~34-42/CD
%/NN
for/IN
HDL-C/NN
,/,
and/CC
~28-50/CD
%/NN
for/IN
LDL-C/NN
,/,
are/VBP
highly/RB
heritable/JJ
in/IN
familial/JJ
T2D/NN
or/CC
diabetic/JJ
patients/NNS
[/(
19/CD
,/,
20/CD
]/)
./.
====================
These/DT
estimates/NNS
indicate/VBP
that/IN
genetic/JJ
variants/NNS
play/VBP
important/JJ
roles/NNS
in/IN
explaining/VBG
inter-individual/JJ
variations/NNS
in/IN
blood/NN
lipid/NN
levels/NNS
./.
====================
Although/IN
systematic/JJ
reviews/VBZ
have/VBP
reported/VBN
relationships/VBZ
between/IN
childhood/NN
obesity/NN
and/CC
adult/JJ
CVD/NN
risk/NN
[/(
21/CD
,/,
22/CD
]/)
,/,
there/EX
is/VBZ
not/RB
a/DT
shred/JJ
of/IN
evidence/NN
that/IN
blood/NN
lipid/NN
status/NN
in/IN
adults/NNS
is/VBZ
an/DT
independent/JJ
or/CC
dependent/JJ
risk/NN
factor/NN
in/IN
a/DT
childhood/NN
obesity/NN
group/NN
./.
====================
Early/JJ
childhood/NN
obesity/NN
might/MD
be/VB
the/DT
best/JJS
time/NN
for/IN
dyslipidemia/NN
intervention/NN
,/,
including/VBG
screening/NN
,/,
early/JJ
detection/NN
,/,
and/CC
management/JJ
./.
====================
The/DT
aim/NN
of/IN
this/DT
study/NN
was/VBD
to/TO
consolidate/VB
the/DT
associations/NNS
of/IN
16/CD
GWAS-based/JJ
candidate/NN
variants/NNS
with/IN
blood/NN
lipid/NN
concentrations/NNS
across/IN
the/DT
lifespan/NN
./.
====================
In/IN
GWAS-based/JJ
candidate/NN
approaches/NNS
,/,
the/DT
well-known/JJ
LPL/NN
gene/NN
was/VBD
significantly/RB
associated/VBN
with/IN
low/JJ
TG/NN
and/CC
high/JJ
HDL-C/NN
levels/NNS
in/IN
a/DT
childhood/NN
obesity/NN
study/NN
,/,
respectively/RB
./.
====================
This/DT
finding/NN
is/VBZ
well/RB
matched/VBN
to/TO
the/DT
negative/JJ
correlation/NN
between/IN
blood/NN
TG/NN
and/CC
HDL-C/NN
concentrations/NNS
[/(
23/CD
]/)
./.
====================
In/IN
addition/NN
,/,
the/DT
LIPC/NN
gene/NN
was/VBD
further/RBR
observed/VBN
in/IN
decreased/VBN
HDL-C/NN
./.
====================
In/IN
analyses/NNS
of/IN
the/DT
joint/NN
effects/NNS
of/IN
these/DT
variants/NNS
,/,
we/PRP
found/VBD
that/IN
GRSs/NNS
on/IN
the/DT
two/CD
risk/NN
alleles/NNS
(/(
rs10503669/CD
at/IN
LPL/NN
and/CC
rs16940212/NN
at/IN
LIPC/NN
)/)
were/VBD
associated/VBN
with/IN
a/DT
cumulative/JJ
effect/NN
of/IN
TG/NN
and/CC
HDL-C/NN
levels/NNS
./.
====================
However/RB
,/,
these/DT
facts/NNS
indicate/VBP
that/IN
currently/RB
identified/VBN
risk/NN
variants/NNS
might/MD
have/VB
low/JJ
discriminatory/JJ
ability/NN
and/CC
modest/VBP
genetic/JJ
contribution/NN
to/TO
disease/NN
prediction/NN
[/(
24/CD
]/)
./.
====================
Lipoprotein/NN
lipase/NN
(/(
LPL/NN
)/)
plays/VBZ
an/DT
important/JJ
role/NN
in/IN
lipid/NN
metabolism/NN
by/IN
hydrolyzing/VBG
TGs/NNS
of/IN
circulating/VBG
chylomicrons/NNS
and/CC
very/RB
low-density/JJ
lipoproteins/NNS
./.
====================
In/IN
addition/NN
,/,
LPL/NN
is/VBZ
expressed/VBN
in/IN
the/DT
brain/NN
regions/NNS
that/IN
are/VBP
functionally/RB
relevant/JJ
to/TO
learning/VBG
,/,
memory/NN
,/,
and/CC
other/JJ
cognitive/JJ
functions/NNS
./.
====================
Many/JJ
GWASs/NNS
and/CC
meta-analyses/NNS
have/VBP
shown/VBN
that/IN
variations/NNS
in/IN
the/DT
well-known/JJ
LPL/NN
gene/NN
for/IN
multiple/JJ
lipid-related/JJ
traits/VBZ
are/VBP
implicated/VBN
in/IN
multiethnic/JJ
populations/NNS
[/(
2/CD
,/,
3/CD
,/,
9/CD
,/,
25-28/CD
]/)
./.
====================
An/DT
increasing/VBG
number/NN
of/IN
studies/NNS
have/VBP
suggested/VBN
an/DT
association/NN
of/IN
LPL/NN
gene/NN
variants/NNS
with/IN
the/DT
risk/NN
of/IN
cerebrovascular/JJ
as/IN
well/RB
as/IN
CVD/NN
[/(
29/CD
]/)
./.
====================
Recent/JJ
genome-wide/NN
investigations/NNS
identified/VBN
schizophrenia-associated/VBN
loci/NNS
in/IN
the/DT
chromosome/NN
8p22/NN
region/NN
,/,
including/VBG
LPL/NN
[/(
30-32/CD
]/)
./.
====================
It/PRP
was/VBD
suggested/VBN
that/IN
LPL/NN
is/VBZ
an/DT
attractive/JJ
candidate/NN
gene/NN
that/WDT
might/MD
be/VB
involved/VBN
in/IN
the/DT
potential/JJ
role/NN
of/IN
lipid/NN
metabolism/NN
in/IN
schizophrenia/NN
./.
====================
Stages/NNS
of/IN
early/JJ
childhood/NN
development/NN
can/MD
be/VB
taken/VBN
into/IN
account/VBP
when/WRB
considering/VBG
a/DT
diagnosis/NN
of/IN
mental/JJ
illness/NN
[/(
33/CD
]/)
./.
====================
Hepatic/JJ
lipase/NN
(/(
LIPC/NN
)/)
gene/NN
encodes/VBZ
hepatic/JJ
triglyceride/NN
lipase/NN
,/,
which/WDT
is/VBZ
expressed/VBN
in/IN
liver/NN
./.
====================
LIPC/NN
has/VBZ
a/DT
dual/JJ
function/NN
as/IN
a/DT
triglyceride/NN
hydrolase/NN
and/CC
ligand/bridging/JJ
factor/NN
for/IN
receptor-mediated/JJ
lipoprotein/NN
uptake/NN
./.
====================
A/DT
GWAS/NN
has/VBZ
identified/VBN
a/DT
possible/JJ
role/NN
of/IN
LIPC/NN
in/IN
advanced/JJ
age-related/JJ
macular/JJ
degeneration/NN
(/(
AMD/NN
)/)
[/(
34/CD
]/)
./.
====================
AMD/NN
is/VBZ
an/DT
eye/NN
condition/NN
affecting/VBG
the/DT
central/JJ
part/NN
of/IN
the/DT
retina/NN
./.
====================
Although/IN
a/DT
condition/NN
that/DT
is/VBZ
commonly/RB
associated/VBN
with/IN
the/DT
elderly/JJ
,/,
macular/JJ
degeneration/NN
affects/VBZ
younger/JJR
people/NN
through/IN
a/DT
rare/JJ
inherited/VBN
condition/NN
[/(
35/CD
]/)
./.
====================
Based/VBN
on/IN
a/DT
lack/NN
of/IN
direct/JJ
relationships/NNS
between/IN
HDL-C/NN
and/CC
AMD/NN
risk/NN
,/,
the/DT
LIPC/NN
association/NN
may/MD
not/RB
be/VB
the/DT
result/NN
of/IN
an/DT
effect/NN
on/IN
HDL-C/NN
levels/NNS
,/,
but/CC
it/PRP
could/MD
represent/VB
a/DT
pleiotropic/JJ
effect/NN
as/IN
a/DT
functional/JJ
component/NN
,/,
such/JJ
as/IN
a/DT
lipoprotein/NN
transporter/RB
,/,
underlying/VBG
the/DT
biological/JJ
mechanisms/NNS
involving/VBG
the/DT
cholesterol/NN
pathway/NN
./.
====================
Taken/VBN
together/RB
,/,
our/PRP$
findings/NNS
demonstrate/VBP
that/IN
the/DT
genetic/JJ
architecture/NN
of/IN
circulating/VBG
lipid/NN
levels/NNS
(/(
TG/NN
and/CC
HDL-C/NN
)/)
overlap/VBP
to/TO
a/DT
large/JJ
extent/NN
in/IN
childhood/NN
as/IN
well/RB
as/IN
in/IN
adulthood/NN
./.
====================
A/DT
genetic/JJ
risk/NN
assessment/NN
by/IN
incorporating/VBG
two/CD
risk/NN
alleles/NNS
suggests/VBZ
encouraging/VBG
evidence/NN
that/IN
identified/VBD
genetic/JJ
risk/NN
variants/NNS
for/IN
lipid/NN
phenotypes/NNS
have/VBP
cumulative/JJ
effects/NNS
on/IN
lipid/NN
concentrations/NNS
./.
====================
Post-GWAS/JJ
functional/JJ
characterization/NN
of/IN
these/DT
variants/NNS
is/VBZ
further/RBR
required/VBN
to/TO
elucidate/VB
the/DT
pathophysiological/JJ
role/NN
and/CC
biological/JJ
mechanisms/NNS
./.
====================
Combined/JJ
effects/NNS
of/IN
risk/NN
alleles/NNS
on/IN
high-density/JJ
lipoprotein/NN
cholesterol/NN
(/(
HDL-C/NN
)/)
./.
====================
Allelic/JJ
dosage/NN
scores/VBZ
are/VBP
plotted/VBN
on/IN
the/DT
X/NN
axis/NN
./.
====================
The/DT
histogram/NN
(/(
Y/NN
axis/NN
on/IN
left/NN
,/,
grey/PRP
bars/VBZ
)/)
represents/VBZ
the/DT
percentage/NN
of/IN
individuals/NNS
in/IN
each/DT
risk/NN
allele/NN
category/NN
./.
====================
The/DT
histogram/NN
(/(
Y/NN
axis/NN
on/IN
right/JJ
,/,
black/JJ
bars/VBZ
)/)
represents/VBZ
mean/NN
HDL-C/NN
concentrations/NNS
./.
====================
(/(
A/NN
)/)
Eight/CD
single/JJ
nucleotide/NN
polymorphisms/NNS
(/(
SNPs/NNS
)/)
including/VBG
the/DT
risk/NN
alleles/NNS
(/(
rs10503669/NN
at/IN
LPL/NN
and/CC
rs16940212/NN
at/IN
LIPC/NN
)/)
./.
====================
(/(
B/NN
)/)
Six/CD
SNPs/NNS
without/IN
the/DT
risk/NN
alleles/NNS
(/(
rs10503669/NN
at/IN
LPL/NN
and/CC
rs16940212/NN
at/IN
LIPC/NN
)/)
./.
====================
Combined/JJ
effects/NNS
of/IN
risk/NN
alleles/NNS
on/IN
triglyceride/NN
(/(
TG/NN
)/)
./.
====================
Allelic/JJ
dosage/NN
scores/VBZ
are/VBP
plotted/VBN
on/IN
the/DT
X/NN
axis/NN
./.
====================
The/DT
histogram/NN
(/(
Y/NN
axis/NN
on/IN
left/NN
,/,
grey/PRP
bars/VBZ
)/)
represents/VBZ
the/DT
percentage/NN
of/IN
individuals/NNS
in/IN
each/DT
risk/NN
allele/NN
category/NN
./.
====================
The/DT
histogram/NN
(/(
Y/NN
axis/NN
on/IN
right/JJ
,/,
black/JJ
bars/VBZ
)/)
represents/VBZ
mean/NN
TG/NN
concentrations/NNS
./.
====================
(/(
A/NN
)/)
Five/CD
single/JJ
nucleotide/NN
polymorphisms/NNS
(/(
SNPs/NNS
)/)
including/VBG
the/DT
risk/NN
allele/NN
(/(
rs10503669/NN
at/IN
LPL/NN
)/)
./.
====================
(/(
B/NN
)/)
Four/CD
SNPs/NNS
without/IN
the/DT
risk/NN
allele/NN
(/(
rs10503669/NN
at/IN
LPL/NN
)/)
./.
====================
Descriptive/JJ
statistics/NNS
of/IN
variables/NNS
for/IN
each/DT
study/NN
cohort/VBP
====================
Association/NN
between/IN
SNPs/NNS
and/CC
lipid-related/JJ
traits/VBZ
in/IN
the/DT
population/NN
with/IN
discovery/NN
sets/NNS
and/CC
replication/NN
study/NN
====================
